Arthur Riggs Diabetes

Oct 14, 2024 | link.springer.com | Arthur Riggs Diabetes

Abstractp21 (CDC42/RAC1) activated kinase 1 (PAK1) is depleted in type 2 diabetic human islets compared with non-diabetic human islets, and acute PAK1 restoration in the islets can restore insulin secretory function ex vivo. We hypothesised that beta cell-specific PAK1 enrichment in vivo can mitigate high-fat-diet (HFD)-induced glucose intolerance by increasing the functional beta cell mass. Human islets expressing exogenous PAK1 specifically in beta cells were used for bulk RNA-seq.

Jul 23, 2024 | cardiab.biomedcentral.com | Zhen Bouman |Arthur Riggs Diabetes |Endovascular Surgery |Naseeb Kaur

ReferencesSun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. PubMed  Google Scholar  Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besancon S, Bommer C, Esteghamati A, Ogurtsova K, Zhang P, et al.

Apr 15, 2024 | diabetesjournals.org | Kansas City |Arthur Riggs Diabetes

Mixed-meal tolerance test–stimulated area under the curve (AUC) C-peptide at 12–24 months represents the primary end point for nearly all intervention trials seeking to preserve β-cell function in recent-onset type 1 diabetes. We hypothesized that participant benefit might be detected earlier and predict outcomes at 12 months posttherapy. Such findings would support shorter trials to establish initial efficacy.

Jan 11, 2024 | link.springer.com | Arthur Riggs Diabetes

AbstractAll forms of diabetes result from insufficient functional beta cell mass. Due to the relatively limited expression of several antioxidant enzymes, beta cells are highly vulnerable to pathological levels of reactive oxygen species (ROS), which can lead to the reduction of functional beta cell mass. During early postnatal ages, both human and rodent beta cells go through a burst of proliferation that quickly declines with age.

Aug 12, 2023 | cell.com | Arthur Riggs Diabetes |Ralph J. DeBerardinis

Highlights•Reductive carboxylation occurs in the absence of lipogenesis•FASN deficiency induces reductive carboxylation•FASN deficiency induces a net cytosol-to-mitochondria citrate flux•Malignant cells trade off lipogenesis-supported rapid growth for redox capacitySummaryFatty acid synthase (FASN) maintains de novo lipogenesis (DNL) to support rapid growth in most proliferating cancer cells.